Medtechs Told: Change Commercial Models Or Be Left Behind
Executive Summary
Medical device companies working on the global stage are undergoing price and innovation productivity pressures just at the time that the markets are demanding a different type of service delivery from their suppliers. Smart manufacturers are reacting positively, with new commercial models, but they remain the exception to the rule, says the Boston Consulting Group, which is soon to release the second edition of its commercial benchmarking initiative.
You may also be interested in...
UK MHRA In The Spotlight As Cumberlege Review Puts Medtech Safety At The Top Of Health Agenda
The findings of the Cumberlege Review into how safety issues for three medical product groups were handled will shape debate on the UK’s new devices legislation, now going through parliament. The MHRA’s devices regulatory activity also comes in for scrutiny.
UK Medtechs Fear That Pre-COVID-19 Activity May Be Over A Year Away
Top of the agenda for the medtech industry globally is when the “new normal” will return. In the UK, the expectations are that post-COVID-19 health care activity will increase gradually, but it is possible that the National Health Service will not reach its pre-coronavirus capacities until late in 2021, “if at all.”
UK NHS Urged To 'Bottle COVID-19 Spirit' For Future Health System Change
Residual resistance to digital health care solutions in the UK NHS disappeared “almost overnight” when COVID-19 compelled the rapid adoption of new tools to meet the surge in demand and cope with supply challenges.
Need a specific report? 1000+ reports available
Buy Reports